Abivax reports 2021 financial results and operations update

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022

Related Keywords

Japan ,Germany ,Paris ,France General ,France ,United Kingdom ,Belarus ,Italy ,San Diego ,California ,United States ,Houston ,Texas ,Russia ,Spain ,Ukraine ,Ukrainian ,Pbruce Sands ,William Sandborn ,Kepler Cheuvreux ,Enregistrement Universel ,Hartmut Ehrlich ,Scripps Md Anderson Cancer Center ,Md Anderson Cancer Center ,American College Of Rheumatology ,Company Board Of Directors On ,Research Tax Credit ,European Medicines Agency ,Bristol Myers Squibb ,Euronext ,Euronext Paris ,Mayo Score ,Cancer Center ,Annual Shareholders ,French Autorit ,Des March ,Modified Mayo Score ,American College ,Abivax Stock Exchange ,News ,Information ,Press Release ,Abivax ,Biotechnology ,Company ,Developing ,Novel ,Therapies ,Hat ,Modulate ,The ,Immune ,System ,O ,Treat ,Hronic ,Inflammatory ,Viral ,End ,Oday ,Nnounces Abvx Fr0012333284 ,